← All trials
NCT00671138
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2007
- Primary completion
- Dec 1, 2008
- Completion date
- Sep 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of SydneyLead sponsor
- James Cook University Hospital, Middlesbrough, UKOverall official - principal investigator
- University of QueenslandStudy director
- Envoi PathologyStudy director
- Walter and Eliza Hall Institute of Medical ResearchStudy director
- University of QueenslandCollaborator
- The Broad FoundationCollaborator
- Walter and Eliza Hall Institute of Medical ResearchCollaborator
- James Cook University Hospital, Middlesbrough, UKStudy director
- James Cook University Hospital, Middlesbrough, UKCollaborator
- University of SydneyReponsible party - principal investigator
- University of SydneyStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.